The ENA virtual meeting 2020

Bevacizumab-induced hypertension and proteinuria: A genome-wide analysis of more than 1,000 patients

Adagrasib in advanced/metastatic NSCLC with KRAS G12C mutation

Development of novel inhibitors of KRASG12C

Impact of angiotensin II pathway inhibition on tumour response to anti PD(L)1 based therapy

Critical issues in drug and biomarker development

Treating elderly cancer patients during the COVID-19 pandemic

Pragmatic geriatric assessment for cancer patients in Brazil

Updates in radiation oncology from SIOG 2020

Biomarker-driven clinical trials: promises and pitfalls

Key themes, highlights and importance of this year's IBCD 2020 meeting

How current assay approval policies are leading to unintended imprecision medicine